Neuroscience and Pain Research Lab, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, Uttar Pradesh, 221 005, India.
Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, St. Petersburg, Pr. Torez 44, Russia.
Eur J Pharmacol. 2020 Dec 15;889:173619. doi: 10.1016/j.ejphar.2020.173619. Epub 2020 Oct 2.
Neuropathic pain is a critical burdensome problem due to the complex interplay of several pathological mechanisms and lack of availability of effective therapeutic interventions. The available therapeutic options are associated with a variety of limitations, including severe side effects, and unmet medical needs, warranting further research to identify and validate potential targets. Adenosine receptors system is a widely studied target, which evidently was successful in alleviation of neuropathic pain in several experimental paradigms, and researchers are putting efforts in building its clinical roadmap. The adenosine receptors act by different mechanisms and targeting adenosine receptors for neuropathic pain includes several important pathways such as p38-mitogen-activated protein kinases (MAPK), extracellular signal-regulated kinases (ERK), brain-derived neurotrophic factor (BDNF) signalling, γ-aminobutyric acid (GABA) as well as the ion channel modulations. Various studies have also shown the relevance of targeting adenosine receptors in chemotherapy-induced neuropathic pain and diabetic neuropathy. Several drugs acting on adenosine receptors have undergone clinical trials for management of neuropathic pain, whereas many other drugs are yet to be studied to find a potential anti-nociceptive agent. In this review, we have discussed the roadmap of adenosine receptors as a potential target for the treatment of neuropathic pain.
神经病理性疼痛是一个严重的负担性问题，这是由于多种病理机制的复杂相互作用以及缺乏有效的治疗干预措施所致。现有的治疗选择存在多种局限性，包括严重的副作用和未满足的医疗需求，因此需要进一步研究以确定和验证潜在的靶点。腺苷受体系统是一个广泛研究的靶点，在几种实验模型中明显成功缓解了神经病理性疼痛，研究人员正在努力构建其临床路线图。腺苷受体通过不同的机制发挥作用，针对神经病理性疼痛的腺苷受体包括几个重要途径，如 p38-丝裂原活化蛋白激酶 (MAPK)、细胞外信号调节激酶 (ERK)、脑源性神经营养因子 (BDNF) 信号转导、γ-氨基丁酸 (GABA) 以及离子通道调节。多项研究还表明，针对腺苷受体在化疗诱导的神经病理性疼痛和糖尿病性神经病变中的相关性。有几种作用于腺苷受体的药物已在临床试验中用于治疗神经病理性疼痛，而许多其他药物仍有待研究以寻找潜在的镇痛剂。在这篇综述中，我们讨论了作为神经病理性疼痛治疗潜在靶点的腺苷受体的路线图。
